Results
1
-
10
of
130
<
1
2
3
...
12
13
>
N. Nagel, H. Schweitzer, H. Urbach, W. Heyse, B. Müller and H. Berchtold.
Ramipril
,
Acta Cryst. (2001). E57, o463-o465Â Â Â Â
[DOI: 10.1107/S1600536801006948]
[DOI: 10.1016/j.bmc.2013.05.031]
Investigation of effects of Lacidipine, Ramipril and Valsartan on DNA damage and oxidative stress occurred in acute and chronic periods following isoproterenol-induced myocardial infarct in rats.
,
Molecular and Cellular Biochemistry
[DOI: 10.1007/s11010-009-0080-y]
How to improve duration and efficiency of the antiproteinuric response to Ramipril: RamiPROT-a prospective cohort study.
,
Journal of Nephrology
[DOI: 10.1007/s40620-015-0256-3]
The renin-angiotensin receptor blocker azilsartan medoxomil compared with the angiotensin-converting enzyme inhibitor ramipril in clinical trials versus routine practice: insights from the prospective EARLY registry.
,
Trials
[DOI: 10.1186/s13063-015-1100-8]
Renin inhibition ameliorates renal damage through prominent suppression of both angiotensin I and II in human renin angiotensinogen transgenic mice with high salt loading.
,
Clinical and Experimental Nephrology
[DOI: 10.1007/s10157-013-0893-6]
Olmesartan vs. ramipril in elderly hypertensive patients: review of data from two published randomized, double-blind studies.
,
High Blood Pressure & Cardiovascular Prevention
[DOI: 10.1007/s40292-013-0037-9]
Antihypertensive efficacy of olmesartan medoxomil and ramipril in elderly patients with mild to moderate hypertension grouped according to renal function status : a retrospective analysis.
,
High Blood Pressure & Cardiovascular Prevention
[DOI: 10.1007/BF03297633]
Antihypertensive efficacy and safety of olmesartan medoxomil and ramipril in elderly mild to moderate essential hypertensive patients with or without metabolic syndrome: a pooled post hoc analysis of two comparative trials.
,
Drugs & Aging
[DOI: 10.1007/s40266-012-0030-3]
<
1
2
3
...
12
13
>